Mdig shapes 3D chromatin architecture of immune checkpoint genes and limits metastasis of triple negative breast cancer cells
Authors:
- Ziwei WangZWZiwei Wang
- Ziqi LiuZLZiqi Liu
- Chitra ThakurCTChitra Thakur
- Yiran QiuYQYiran Qiu
- Jun WangJWJun Wang
- Mehdi DamaghiMDMehdi Damaghi
- John D HaleyJHJohn D Haley
- Fei ChenFCFei Chen
Preprint
Abstract
Despite decades of progress in metastasis research, the identity of bona fide metastasis-driving genes remains elusive. By shifting the focus from individual genes to the three-dimensional (3D) architecture of the genome, we identify the mineral dust-induced gene (mdig) as a chromatin-topology regulator that suppresses immune-checkpoint activation and metastasis in triple-negative breast cancer (TNBC). Re-expression of mdig in mdig-knockout (KO) cells markedly reduced liver metastasis, whereas mdig loss activated epithelial-mesenchymal transition (EMT), T-cell exhaustion, and antigen-presentation pathways. Across multiple cancer types, high mdig expression predicted improved responses to immune checkpoint blockade (ICB). Mechanistically, mdig depletion derepressed inhibitory checkpoint genes, including PD-L1, PD-L2, LGALS9, and PLXNB1/2, accompanied by increased H3K9me3 and H3K36me3 at these loci. Hi-C profiling revealed that mdig maintains topologically associating domains (TADs) and long-range repressive loops at checkpoint loci; loss of mdig disrupted these structures, enabling coordinated activation of immune-evasion programs. Genome-wide analyses showed extensive TAD remodeling in mdig KO cells, with pronounced alterations on chromosome X. Collectively, these findings position mdig as a key chromatin-architectural regulator of immune evasion and metastatic behavior, underscoring its potential as a biomarker for ICB responsiveness in TNBC and beyond.Keywords
Funding Information
- National Institutes of Health (NIH) (R01 ES031822, R01 ES028335, R01 ES028263)
- Research Start-up fund of the Stony Brook University
- Baldwin Breast Cancer Research foundation
- American Cancer Society